CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis (LAdoRIC)

Civil Hospices of Lyon

Status: Completed

Conditions: Psoriatic Arthritis; Rheumatoid Arthritis

Treatments: Other: Multi-parametric Flow Cytometry analysis on patients and healthy donors samples

Study type: Observational

Funder types: Other

Identifiers

NCT03953378

LAdoRIC

Details and patient eligibility

About

Prospective study to investigate the correlation between CD39/CD73 expression by the different T lymphocyte subpopulations in the blood and synovial fluid (if available) into patients with chronic inflammatory rheumatism RA and PsA types, with the rheumatic activity, the background therapy (with Methotrexate (MTX)) and the response to this treatment.

Full description

Th1.17 compose a recently described subset of highly polyfunctional and thus potentially more harmful CD4+ effector T cells (Teff) than classical Th17 as they co-produce interferon-γ (IFN-γ) and interleukin-17A (IL-17A). For this reason, Th1.17 rise increasing interest in RA and PsA since they seem involved in their pathophysiology. Hyper activation of Teff in RA and PsA results partly from a deficiency in regulatory mechanisms of Teff's pro-inflammatory functions. The ecto-nucleotidase CD73 delineates Teff enriched in Th1.17 features and acts as a regulatory mechanism for these pro-inflammatory cells. Considering that MTX, usually used as first line treatment of RA and PsA, increases extracellular concentrations of adenosine monophasphate (AMP) and immunosuppressive adenosine, the investigators hypothesized that CD4+CD73+ T cell effector population enriched in Th1.17 and Th17 cells may participate in the pathogenicity of RA and PsA but also in the resistance to MTX treatment through the specific expression of CD73 essential for Ado generation and which is down-regulated on proliferating T cells.

Enrollment: 41 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged ≥ 18 years
• Patients naive to biologics
• Patients with RA fulfilling the American College of Rheumatology and European League Against Rheumatism 2009 criteria
• Patients with PsA fulfilling the Classification for PsA (CASPAR) criteria

Exclusion criteria

• None

Trial design

41 participants in 3 patient groups

Group "RA patients"

Description:

Patients with Rheumatoid Arthritis (RA) fulfilling the American College of Rheumatology and European League Against Rheumatism 2009 criteria.

Treatment:

Other: Multi-parametric Flow Cytometry analysis on patients and healthy donors samples

Group "PsA patients"

Description:

Patients with Psoriatic Arthritis (PsA) fulfilling the Classification for PsA (CASPAR) criteria.

Treatment:

Other: Multi-parametric Flow Cytometry analysis on patients and healthy donors samples

Group "Healthy donors"

Description:

Anonymous healthy donors from the Etablissement Français du Sang.

Treatment:

Other: Multi-parametric Flow Cytometry analysis on patients and healthy donors samples